An Open-Label, Randomized, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV to Engerix-B and Fendrix in Adults on Hemodialysis Who Have Previously Received Hepatitis B Vaccination and Are Not Seroprotected.
Phase of Trial: Phase III
Latest Information Update: 08 Mar 2017
At a glance
- Drugs V 270 (Primary) ; Hepatitis B vaccine recombinant
- Indications Hepatitis B
- Focus Pharmacodynamics; Registrational
- Sponsors Dynavax Technologies
- 12 Jan 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 12 Jan 2011 Actual initiation date (Dec 2010) added as reported by ClinicalTrials.gov.
- 15 Sep 2010 New trial record
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History